CTLA4 and ovarian cancer: Combining CTLA-4 blockade with the demethylating agent decitabine in a murine ovarian cancer model led to elevated differentiation of naïve into effector T cells, extended responses of cytotoxic lymphocytes, and prolonged mouse survival [57].